Update shared on13 Sep 2025
Fair value Increased 6.83%Analysts have raised Oxford Biomedica’s price target from £5.55 to £5.93, citing improved growth prospects, commercial execution, and operational strength, with ongoing share price weakness seen as a potential entry point despite lingering market uncertainties and execution risks.
Analyst Commentary
- Bullish analysts cite an improved growth outlook and enhanced commercial execution as key drivers for the upward price target revision.
- Strong underlying track record and operational excellence recognized as supporting further share price appreciation.
- Continued year-to-date share price weakness presents a potential entry point for upside, assuming company guidance is achieved.
- Uncertainty around near-term market dynamics and limited visibility into pipeline or revenue streams prompt more cautious or bearish outlooks.
- Bearish analysts flag ongoing market risks and execution challenges, leading to lower price targets and neutral recommendations.
What's in the News
- Completed a follow-on equity offering raising £60 million through the issuance of 13,921,114 ordinary shares at £4.31 per share, under Regulation S and subsequent direct listing.
- Previously filed for a follow-on equity offering of £60 million under Regulation S and subsequent direct listing.
- Provided H1 2025 revenue guidance of £70–73 million, indicating 38–44% growth over H1 2024; reiterated full year 2025 revenue guidance of £160–170 million on a constant currency basis.
- Held an Analyst/Investor Day.
Valuation Changes
Summary of Valuation Changes for Oxford Biomedica
- The Consensus Analyst Price Target has risen from £5.55 to £5.93.
- The Future P/E for Oxford Biomedica has fallen from 37.45x to 35.06x.
- The Consensus Revenue Growth forecasts for Oxford Biomedica has risen slightly from 25.6% per annum to 26.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.